Drugs / irinotecan liposome (II)
irinotecan liposome (II)
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06332950 | Apr 2024 → Apr 2027 expected | small cell lung carcinoma | Baohui Han | Not yet recruiting | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT06827717 | Apr 2025 → Apr 2027 expected | Ewing sarcoma | Sun Yat-sen University | Recruiting | No outcome recorded |
| Phase 2 | NCT06739928 | Jan 2025 → Jun 2026 overdue | small cell lung carcinoma | Guangzhou Institute of Respiratory Disease | Recruiting | No outcome recorded |
| Phase 2 | NCT06540326 | Nov 2024 → Apr 2026 overdue | colorectal cancer | Second Affiliated Hospital, School of Medicine, Zhejiang University | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Irinotecan liposome (II) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06739928 ↗ |
| Known as | HR070803 | “Drug Irinotecan Hydrochloride Liposome Injection（II）56.5mg/m2, IV infusion administered on day 1 of every 28-day cycle until disease progression, unacceptable toxicity or...” NCT06827717 ↗ |
| Known as | Irinotecan Hydrochloride Liposome Injection（II） | “Drug Irinotecan Hydrochloride Liposome Injection（II）56.5mg/m2, IV infusion administered on day 1 of every 28-day cycle until disease progression, unacceptable toxicity or...” NCT06827717 ↗ |
| Route | Intravenous | “Irinotecan Liposome (II): RP2D, IV, D1, Q3W” NCT06332950 ↗ |